Metabolic Changes Induced by NMN in Healthy Subjects With Acute Binge Drink (NMN-MeABD)
Binge Drinking, Liver Injury, Nutritional Supplementation

About this trial
This is an interventional health services research trial for Binge Drinking focused on measuring β-nicotinamide mononucleotide, Acute alcohol intake, Nutritional supplementation, Liver
Eligibility Criteria
Inclusion Criteria: a. Sign informed consent Exclusion Criteria: Neurological disorders Alcohol allergy Alcohol addiction Gastrointestinal diseases Liver, kidney, cardiovascular or systemic diseases Antibiotics were administered within 2 weeks prior to the trial Participants who ate a vegetarian diet Unable to use a smartphone or computer with Internet access Participate in another intervention study
Sites / Locations
- Zhejiang Chinese Medical UniversityRecruiting
Arms of the Study
Arm 1
Arm 2
Placebo Comparator
Experimental
maltodextrin group
β-nicotinamide mononucleotide group
4 capsule with 1000mg ''maltodextrin''
4 capsule with 1000mg ''β-nicotinamide mononucleotide''